Page last updated: 2024-12-10

cytochalasin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cytochalasin B: A cytotoxic member of the CYTOCHALASINS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311281
CHEMBL ID411729
CHEBI ID23527
SCHEMBL ID20063279
MeSH IDM0005580

Synonyms (69)

Synonym
MLS001148651
c29h37no5
smr000058787
MLS000028816 ,
phomin
SPECTRUM5_001780
2h-oxacyclotetradec(2,3-d)isoindole-2,18(5h)-dione, 16-benzyl-6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-, (e)-(5s,9r,12as,13s,15s,15as,16as,18as)-
7,20-dihydroxy-10-phenyl-5,16-dimethyl-24-oxa-(14)cytochalas-6(12),13,21-trien-23-one
2h-oxacyclotetradec(2,3-d)isoindole-2,18(5h)-dione, 16-benzyl-6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-, (e,e)-(5s,9r,12as,13s,15s,15as,16s,18as)-
(e,e)-(5s,9r,12as,13s,15s,15as,16s,18as)-16-benzyl-6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-2h-oxacyclotetradec(2,3-d)isoindole-2,18(5h)-dione
hsdb 3479
2h-oxacyclotetradecino(2,3-d)isoindole-2,18(5h)-dione, 16-benzyl-6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-, (e,e)-(5s,9r,12as,13s,15s,15as,16s,18as)-
brn 1096207
einecs 239-000-2
24-oxa(14)cytochalasa-6(12),13,21-triene-1,23-dione, 7,20-dihydroxy-16-methyl-10-phenyl-, (7s,13e,16r,20r,21e)-
7(s),20(r)-dihydroxy-16(r)-methyl-10-phenyl-24-oxa(14)cytochalasa-6(12),13(e),21(e)-triene-1,23-dione
BSPBIO_001600
BCBCMAP01_000011
IDI1_034070
nsc-107658
nsc107658 ,
cytochalasin b
mls002703001 ,
cytochalasin b from drechslera dematioidea, >=98% (hplc), powder
NCGC00163439-02
NCGC00163439-01
LMPK11000002
HMS1989P22
CHEMBL411729
chebi:23527 ,
HMS1361P22
HMS1791P22
unii-3chi920qs7
ccris 9284
2h-oxacyclotetradecino(2,3-d)isoindole-2,18(5h)-dione, 6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-16-(phenylmethyl)-, (3e,5r,9r,11e,12as,13s,15s,15as,16s,18as)-
3chi920qs7 ,
C19954
cytochalasin beta,helminthosporium dematioideum
CCG-39777
cytochalasin b from drechslera dematioidea
rothweiler
cytochalasin b [hsdb]
2h-oxacyclotetradecino(2,3-d)isoindole-2,18(5h)-dione, 16-benzyl-6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-, (e,e)-(5r,9r,12as,13s,15s,15as,16s,18as)-
cytochalasin b [mi]
2h-oxacyclotetradecino(2,3-d)isoindole-2,18(5h)-dione, 6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-16-(phenylmethyl)-, (5r-(3e,5r*,9r*,11e,12as*,13s*,15s*,15as*,16s*,18as*))-
cytochalasin b from helminthosporium dematioideum
gtpl5334
AKOS025311470
REGID_FOR_CID_5311281
(3e,5r,9r,11e,12as,13s,15s,15as,16s,18as)-16-benzyl-5,13-dihydroxy-9,15-dimethyl-14-methylidene-6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-2h-oxacyclotetradecino[2,3-d]isoindole-2,18(5h)-dione
W-201323
(3e,5r,9r,11e,12as,13s,15s,15as,16s,18as)-6,7,8,9,10,12a,13,14,15,15a,16,17-dodecahydro-5,13-dihydroxy-9,15-dimethyl-14-methylene-16-(phenylmethyl)-2h-oxacyclotetradecino[2,3-d]isoindole-2,18(5h)-dione
HMS3402P22
OPERA_ID_1877
mfcd00077704
CS-0012975
HY-16928
cytochalasin b from drechslera dematioidea, >=97.0% (hplc)
GBOGMAARMMDZGR-TYHYBEHESA-N
bdbm50478403
SCHEMBL20063279
DTXSID30893482
(1s,4e,6r,10r,12e,14s,15s,17s,18s,19s)-19-benzyl-6,15-dihydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,21-dione
(3s,3as,4s,6s,6as,7e,10r,14r,15e,181s)-3-benzyl-6,14-dihydroxy-4,10-dimethyl-5-methylene-3,3a,4,5,6,6a,9,10,11,12,13,14-dodecahydro-1h-[1]oxacyclotetradeca[2,3-d]isoindole-1,17(2h)-dione
Q26998028
11032-95-4
cytochalasin b (phomin)
cytochalasin-b
(4z,12z)-19-benzyl-6,15-dihydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,21-dione

Research Excerpts

Overview

Cytochalasin B (CB) is a cell-permeable mycotoxin. It is a cytokinesis inhibitor that preferentially enlarges and multinucleates malignant cells, making them much more sensitive to ultrasonic irradiation. It also impairs the actin cytoskeleton leading to undesired toxicity.

ExcerptReferenceRelevance
"Cytochalasin B (CB) is a cell-permeable mycotoxin. "( Cytochalasin B induces apoptosis through the mitochondrial apoptotic pathway in HeLa human cervical carcinoma cells.
Hwang, J; Jung, JH; Kim, DK; Xu, Y; Yi, M; Zhang, X, 2013
)
3.28
"Cytochalasin B is a cytokinesis inhibitor that preferentially enlarges and multinucleates malignant cells, making them much more sensitive to ultrasonic irradiation."( The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells.
Acquafondata, C; Christen, T; Fondy, TP; Trendowski, M; Wong, V; Yu, G, 2014
)
1.44
"Cytochalasin B is a mycogenic toxin that preferentially damages malignant cells through multiple mechanisms. "( Enlargement and multinucleation of u937 leukemia and MCF7 breast carcinoma cells by antineoplastic agents to enhance sensitivity to low frequency ultrasound and to DNA-directed anticancer agents.
Fondy, TP; Trendowski, M; Wong, V; Yu, G, 2015
)
1.86
"Cytochalasin B is a potentially novel microfilament-directed chemotherapeutic agent that prevents actin polymerization, thereby inhibiting cytokinesis. "( Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration.
Acquafondata, C; Corsette, CM; Fondy, TP; Mitchell, JM; Trendowski, M, 2015
)
2.1
"Cytochalasin B (CB) is a potent natural glucose import inhibitor which also impairs the actin cytoskeleton leading to undesired toxicity."( Trienamine catalyzed asymmetric synthesis and biological investigation of a cytochalasin B-inspired compound collection.
Antonchick, AP; Schwalfenberg, M; Sellstedt, M; Waldmann, H; Ziegler, S, 2016
)
1.39
"Cytochalasin B (CB) is an actin polymerization inhibitor that can significantly affect cell activity and is often used in studies concerning cytology."( Effects of cytochalasin B on DNA methylation and histone modification in parthenogenetically activated porcine embryos.
Hou, X; Li, Z; Liu, J; Sun, L; Tang, B; Wang, Y; Wang, Z; Zhai, Y; Zhang, X; Zhang, Z, 2016
)
1.55
"Cytochalasin B (CB) is a toxic microfilament-inhibiting agent that is known to relax the cytoskeleton and enhance the flexibility of oocytes."( Cytochalasin B treatment of mouse oocytes during intracytoplasmic sperm injection (ICSI) increases embryo survival without impairment of development.
Hu, LL; Jin, LH; Lei, L; Liu, ZH; Shen, XH; Wang, ZD; Zheng, Z, 2012
)
2.54
"Cytochalasin B binding is a useful method in the identification of the glucose transporter in human cells, but the technique may be less useful in other species."( Cytochalasin B does not serve as a marker of glucose transport in rabbit erythrocytes.
Albert, SG, 1984
)
2.43
"Cytochalasin B is a potent mitogen for B-CLL cells and may be useful in cytogenetic studies of this often indolent neoplasm."( Cytochalasin B is a potent mitogen for chronic lymphocytic leukemia cells in vitro.
Larson, RA; Yachnin, S, 1983
)
2.43
"[3H]Cytochalasin B is a high-affinity ligand for the transporter that is displaced by D-glucose."( Identification of the glucose transporter in rat skeletal muscle.
Klip, A; Lienhard, GE; Ransome, KJ; Schroer, DW; Walker, D, 1983
)
0.75
"[3H]Cytochalasin B was found to be a natural photoaffinity ligand which at low concentrations could be photoincorporated into specific proteins of the human erythrocyte plasma membrane associated with high affinity binding sites of this molecule. "( Cytochalasin B. A natural photoaffinity ligand for labeling the human erythrocyte glucose transporter.
Shanahan, MF, 1982
)
2.27
"Cytochalasin B (CB) is a potent inhibitor of sugar transport and cell motility in animal cells. "( 7-Acetylcytochalasin B: differential effects on sugar transport and cell motility.
Lees, A; Lin, S, 1979
)
2.14
"Cytochalasin B is a potent inhibitor of the passive system and allows the cells to establish a sugar gradient that is much higher than normal."( Energetics of sugar transport by isolated intestinal epithelial cells: effects of cytochalasin B.
Kimmich, GA; Randles, J, 1979
)
1.21
"Cytochalasin B is a potent, non-competitive inhibitor of glucose transport at the blood-brain interface."( Cytochalasin B inhibition of brain glucose transport and the influence of blood components on inhibitor concentration.
Betz, AL; Drewes, LR; Gilboe, DD; Horton, RW, 1977
)
2.42
"Cytochalasin B is a potent inhibitor of mammalian passive glucose transporters. "( Cytochalasin B as a probe of protein structure and substrate recognition by the galactose/H+ transporter of Escherichia coli.
Baldwin, SA; Cairns, MT; Henderson, PJ; Horne, P; McDonald, TP, 1991
)
3.17
"Cytochalasin B appears to be an effective mitogen for demonstrating abnormal metaphases in patients with CLL."( Chromosome abnormalities in chronic lymphocytic leukemia revealed by cytochalasin B and Epstein-Barr virus.
Crossen, PE; Godwin, JM; Heaton, DC; Tully, SM, 1987
)
1.23

Effects

Cytochalasin B (CB) has been shown to be a potent depressant of the antigen-induced clone expansion and terminal differentiation of mouse B-lymphocytes to antibody-forming cells. It has no effect on the release of sedimentable acid hydrolases of intact granules obtained from disrupted polymorphonuclear leucocytes.

ExcerptReferenceRelevance
"Cytochalasin B has no effect on chloroplast movement when added alone, but when added with colchicine it prevents colchicine inhibition of movement."( Rhythmic chloroplast migration in the green alga Ulva: dissection of movement mechanism by differential inhibitor effects.
Briggs, WR; Britz, SJ, 1983
)
0.99
"Cytochalasin B has been reported to inhibit fibrinogen binding and aggregation of rabbit platelets in response to ADP. "( Observations on the effects of cytochalasin B and cytochalasin D on ADP- and chymotrypsin-treated platelets.
Peerschke, EI, 1984
)
2
"Cytochalasin B (CB) has been shown to be a potent depressant of the antigen-induced clone expansion and terminal differentiation of mouse B-lymphocytes to antibody-forming cells. "( Cytochalasin A inhibits B-lymphocyte capping and activation by antigens.
La Via, MF; Misefari, A; Teti, G; Venza-Teti, D, 1981
)
1.71
"3. Cytochalasin B (2-50mug/ml) has no effect on the release of sedimentable acid hydrolases of intact granules obtained from disrupted polymorphonuclear leucocytes."( Selective release of lysosomal hydrolases from phagocytic cells by cytochalasin B.
Allison, AC; Davies, P; Haswell, AD, 1973
)
1

Actions

Cytochalasin B is shown to inhibit uptake of 3-O-methylglucose into isolated rat hepatocytes with a Ki = 1.9 microM. It did not inhibit the rapid initial killing of bacteria opsonized with normal mouse serum, but completely inhibited the slower phase of killing.

ExcerptReferenceRelevance
"Cytochalasin B did not enhance this primed glucose response."( Fuel-induced insulin release in vitro from insulinomas transplanted into the rat kidney.
Ferguson, DC; Hoenig, M; Matschinsky, FM, 1984
)
0.99
"Cytochalasin B is shown to inhibit uptake of 3-O-methylglucose into isolated rat hepatocytes with a Ki = 1.9 microM. "( Unique cytochalasin B binding characteristics of the hepatic glucose carrier.
Axelrod, JD; Pilch, PF, 1983
)
2.16
"Cytochalasin B did not inhibit the rapid initial killing of bacteria opsonized with normal mouse serum, but completely inhibited the slower phase of killing."( Natural resistance of mice to Salmonella typhimurium: bactericidal activity and chemiluminescence response of murine peritoneal macrophages.
Blumenstock, E; Jann, K, 1981
)
0.98
"Cytochalasin B did, however, inhibit granulocytic HL60 adherence to fibronectin by 50%, demonstrating that actin polymerization is important for optimal beta 1-dependent granulocytic adherence."( Mechanisms of beta 1 integrin-dependent adherence of granulocytic HL60 to fibronectin.
Bohnsack, JF; Chang, J; Yednock, TA; Zhou, X, 1995
)
1.01
"Cytochalasin B at a lower concentration (4 microM) produced a less marked decrease in responses to noradrenaline in both strains of rats."( Wall tension and contraction of the aorta in 6-month-old spontaneously hypertensive rats.
Guimarães, S; Nunes, JP, 2000
)
1.03
"Cytochalasin B is known to enhance insulin release evoked by nutrient and non-nutrient secretagogues, including D-glucose, despite inhibiting D-glucose uptake and metabolism in pancreatic islets. "( Effects of cytochalasin B and D upon insulin release and pancreatic islet cell metabolism.
Dura, E; Jijakli, H; Malaisse, WJ; Ramirez, R; Sener, A; Zhang, HX, 2002
)
2.15
"Cytochalasin B did not inhibit mucopolysaccharide synthesis, although it did stop ruffling and locomotion."( The role of extracellular materials in cell movement. I. Inhibition of mucopolysaccharide synthesis does not stop ruffling membrane activity or cell movement.
Conrad, GW; Spooner, BS, 1975
)
0.98
"Cytochalasin B appears to inhibit an early stage in the process and colchicine a relatively late stage."( The effects of cytochalasin and colchicine on interferon production.
Ito, Y; Kimura, Y; Kunii, A; Nagata, I; Nishiyama, Y; Shimokata, K, 1976
)
0.98
"Cytochalasin B did not inhibit protein synthesis or transport of [3H]-cholesterol into the cells nor did it alter total cell concentration of ATP."( Response of adrenal tumor cells to adrenocorticotropin: site of inhibition by cytochalasin B.
Hall, PF; Mrotek, JJ, 1977
)
1.21
"Cytochalasin B is shown to inhibit the interconversion but does not interfere with the insulin-induced increase of the mitochondrial calcium pool or with the acceleration of the calcium efflux out of 45C-preloaded myotubes."( Regulation of glycogen synthase interconversion in cultured muscle cells: actions of insulin, calcium, ionophore A 23187 and cytochalasin B.
Gaertner, U; Pette, D; Schudt, C, 1977
)
1.18
"Cytochalasin B did not inhibit ingestion of Chlamydia psittaci by either mouse fibroblasts (L cells) or mouse peritoneal macrophages in concentrations that produced distinctive morphological changes and inhibited phagocytosis of polystyrene latex beads and Escherichia coli K-12."( Cytochalasin B does not inhibit ingestion of Chlamydia psittaci by mouse fibroblasts (L cells) and mouse peritoneal macrophages.
Byrne, GI; Gardner, M; Gregory, WW; Moulder, JW, 1979
)
3.15
"Cytochalasin B was shown to inhibit lysis of antibody-coated target cells by effector cells from rabbit spleen and lymph node. "( Antibody-dependent cytotoxicity: modulation by the cytochalasins and microtubule-disruptive agents.
Gelfand, EW; Morris, SA; Resch, K, 1975
)
1.7
"Cytochalasin B is found to enhance target cell lysis by cytotoxic T lymphocytes when antibody-coated polystyrene beads are used to bridge the cells."( Enhancement of redirected target cell lysis by cytotoxic T lymphocytes in the presence of cytochalasin B.
Kolber, MA, 1991
)
1.22
"Cytochalasin B failed to increase the cytosolic Ca2+ concentration in response to Ins P3 or A23187 and even failed to decrease the cytosolic Ca2+ concentration in response to ATP."( An ATP-dependent and inositol trisphosphate-sensitive Ca2+ pool linked with microfilaments of the parietal cell.
Tsunoda, Y, 1986
)
0.99
"Cytochalasin B did not enhance T cell mitogenesis when given only in the IL-2-dependent late phase."( Cytochalasin B enhances T cell mitogenesis by promoting expression of an interleukin 2 receptor.
Hara, M; Idota, M; Izutsu, K; Komada, H; Nakabayashi, H; Takahashi, T; Takanari, H, 1987
)
2.44
"Cytochalasin B was found to inhibit both NBDG entry and exit."( Asymmetric transport of a fluorescent glucose analogue by human erythrocytes.
Haugland, R; Kutchai, H; Speizer, L, 1985
)
0.99

Treatment

Cytochalasin B treatment increased the amount of G proteins activated by chemoattractant receptors by about 25%. Cytochalatin B-treated growth cones sidestepped laterally along the border instead of turning, and in sidestepping growth cones, microtubules were not bundled and aligned. Cyt B treatment decreased endocellular type I collagen synthesis and the total uptake of 3H-proline.

ExcerptReferenceRelevance
"Cytochalasin B treatment of neutrophils decreased the sensitivity of fMLF-dependent NFPRb recognition 2-fold, from EC50 = 33 ± 8 to 74 ± 21 nM."( Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Bothner, B; Dratz, EA; Gripentrog, JM; Jesaitis, AJ; Keren-Aviram, G; Liu, T; Lord, CI; Maaty, WS; Riesselman, M, 2013
)
1.11
"Cytochalasin B treatment abolished elongation, bundling and branching activities of actin filaments in guard cells, and these changes of actin filaments, and as a result, more chloroplasts were localized at the centre of guard cells."( Stochastic dynamics of actin filaments in guard cells regulating chloroplast localization during stomatal movement.
Gao, XQ; Wang, XC; Wang, XL, 2011
)
1.09
"Cytochalasin B pretreatment of oocytes before vitrification does not help to reduce the damage induced by the cryopreservation process of porcine oocytes."( Effect of cytochalasin B pre-treatment of in vitro matured porcine oocytes before vitrification.
Casares-Crespo, L; Marco-Jiménez, F; Vicente, JS,
)
1.16
"Cytochalasin B (CB) pretreatment to block F-actin reorganization improved oxygenation and reduced BAL inflammatory factors and pulmonary neutrophil sequestration, but did not reduce the adhesive molecules of blood leukocytes."( Actin filament reorganization is a key step in lung inflammation induced by systemic inflammatory response syndrome.
Chen, M; Du, L; Gong, L; Liu, J; Liu, X; Luo, N; Tao, K; Yan, M; Zhang, J; Zhou, J, 2012
)
1.1
"Cytochalasin B pretreatment attenuated p38MAP kinase and JNK effects (p < 0.05) without altering ERK1/2 phosphorylation."( Role of the actin cytoskeleton in angiotensin II signaling in human vascular smooth muscle cells.
Schiffrin, EL; Touyz, RM; Yao, G, 2005
)
1.05
"Cytochalasin b treatment also resulted in curled and looped tails, a phenomenon of hyposmotic stress, and CB and CD caused significant, dose-dependent decreases in motility determined by computer-assisted sperm assessment."( The macaque sperm actin cytoskeleton reorganizes in response to osmotic stress and contributes to morphological defects and decreased motility.
Correa, LM; Meyers, SA; Thomas, A, 2007
)
1.06
"Cytochalasin B treatment of COCs before vitrification exerted a negative effect on oocyte survival."( Morphological and biochemical analysis of immature ovine oocytes vitrified with or without cumulus cells.
Ariu, F; Bogliolo, L; Fois, S; Ledda, S; Leoni, G; Pau, S; Rosati, I; Succu, S; Zedda, MT, 2007
)
1.06
"Cytochalasin B-treated cells secreted approx."( Two distinct mechanisms for stimulation of oxygen-radical production by polymorphonuclear leucocytes.
Campbell, AK; Hallett, MB, 1983
)
0.99
"Cytochalasin B treatment and placement of the macrophages at 4 degrees C before infection inhibited this process by about 99 and 96%, respectively."( Interaction of Trypanosoma cruzi with macrophages in vitro: dissociation of the attachment and internalization phases by low temperature and cytochalasin B.
de Araújo Jorge, TC; de Meirelles, MN; de Souza, W, 1982
)
1.19
"Cytochalasin B-treated cells could be damaged by even small numbers of rickettsiae."( Phospholipase A and the interaction of Rickettsia prowazekii and mouse fibroblasts (L-929 cells).
Miller, ET; Winkler, HH, 1982
)
0.99
"Cytochalasin B (CB) treatment induces or accelerates the capping phenomenon in some cells. "( "Pseudo-cap" formation in Ehrlich ascites tumor cells induced by cytochalasin B.
Awai, M; Kirizuka, K; Mori, M; Nakamoto, S; Sadahira, Y; Sasaki, J; Seno, S; Utsumi, K, 1982
)
1.94
"Cytochalasin B treatment resulted in significant reduction of progesterone production by luteal slices in response to LH and the addition of serum to the medium did not alter this effect."( Regulation of steroidogenesis in the ovine corpus luteum.
Moss, GE; Niswender, GD; Silavin, SL, 1980
)
0.98
"Cytochalasin B pretreatment of tumor cells alters the distribution pattern of metastases after i.v. "( Alteration of a tumor cell distribution pattern by cytochalasin B.
Hagmar, B; Ryd, W, 1981
)
1.96
"Cytochalasin B pretreatment at 40 microM completely blocked the ATP-induced rotation at the anterior end."( Palate morphogenesis: II. Contraction of cytoplasmic processes in ATP-induced palate rotation in glycerinated mouse heads.
Wee, EL; Zimmerman, EF, 1980
)
0.98
"Cytochalasin B treatment inhibited, in a concentration-dependent manner, the synthesis and secretion of GAGs and proteins, and the endocytosis of HA."( Modulation of phenotypic expression of fibroblasts by alteration of the cytoskeleton.
Arena, N; Baroni, T; Becchetti, E; Carinci, P; Evangelisti, R; Locci, P; Rossi, L; Valeno, V, 1995
)
1.01
"In cytochalasin B-treated PMNs, significant O2- generation occurred within 5 min of exposure to fMLP or Aroclor 1242."( Aroclor 1242 stimulates the production of inositol phosphates in polymorphonuclear neutrophils.
Contreras, ML; Ganey, PE; Tithof, PK, 1995
)
0.81
"Cytochalasin B treatment caused disappearance of microfilaments and blocked the stimulatory action of ACTH and DBcAMP on cortisol secretion."( Effects of selective disruption of cytoskeletal elements on steroid secretion by human adrenocortical slices.
Contesse, V; Delarue, C; Feuilloley, M; Lefebvre, H; Vaudry, H, 1994
)
1.01
"When cytochalasin B-treated neutrophils were stimulated with fMet-Leu-Phe (fMLP) in the presence of Ca2+, phospholipase C (PLC) activity, as measured by inositol-1,4,5-triphosphate (IP3) formation, preceded phospholipase D (PLD)-catalyzed breakdown of choline-containing phosphoglycerides to form choline and diradyl-sn-glycero-3-phosphate (phosphatidic acid), suggesting a possible link between PLC and PLD. "( Phospholipase C and phospholipase D are activated independently of each other in chemotactic peptide-stimulated human neutrophils.
Anthes, JC; Billah, MM; Cheewatrakoolpong, B; Egan, RW; Mullmann, TJ; Siegel, MI, 1993
)
0.8
"Cytochalasin B treatment resulted in concentration-dependent inhibition of contraction."( Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo.
Friedman, SL; Housset, CN; Rockey, DC, 1993
)
1.01
"Cytochalasin B treatment following nuclear transfer manipulation seemed not to be beneficial in improving development of cloned embryos (p > 0.05)."( Beneficial effect of oocyte activation prior to and during nuclear transfer in cattle using in vitro matured oocytes 24 h of age.
Du, F; Jiang, S; Yang, X, 1995
)
1.01
"Cytochalasin B treatment increased the amount of G proteins activated by chemoattractant receptors by about 25%."( Translocation of microfilament-associated inhibitory guanine-nucleotide-binding proteins to the plasma membrane in myeloid differentiated human leukemia (HL-60) cells.
Jakobs, KH; Kaldenberg-Stasch, S; Liedel, K; Meyer zu Heringdorf, D; Michel, MC; Wieland, T, 1996
)
1.02
"Cytochalasin B-treated growth cones sidestepped laterally along the border instead of turning, and in sidestepping growth cones, microtubules were not bundled and aligned."( Actin filament bundles are required for microtubule reorientation during growth cone turning to avoid an inhibitory guidance cue.
Challacombe, JF; Letourneau, PC; Snow, DM, 1996
)
1.02
"Cytochalasin B-treatment, which blocks actin reorganization, partly reduced COYP-mediated PLD activity, but had no effect on activity caused by anti-CD18-coated particles."( Activation of phospholipase D is an early event in integrin-mediated signalling leading to phagocytosis in human neutrophils.
Fällman, M; Serrander, L; Stendahl, O, 1996
)
1.02
"In cytochalasin B treatment, the responses were similar to those of colchicine but with less severity."( Opisthorchis viverrini: the effects of colchicine and cytochalasin B on the adult tegument.
Apinhasmit, W; Sobhon, P, 1996
)
1.06
"Cytochalasin B treatment decreased endocellular type I collagen synthesis and the total uptake of 3H-proline, while enhanced collagen secretion."( Involvement of the cytoskeleton in regulation of collagen synthesis and secretion.
Becchetti, E; Bodo, M; Carinci, P; Evangelisti, R, 1995
)
1.01
"Cytochalasin B (Cyt B)-treated lymphocyte cultures from three females (aged 28, 42 and 72) were analyzed."( The application of spectral karyotyping (SKY) and fluorescent in situ hybridization (FISH) technology to determine the chromosomal content(s) of micronuclei.
Jackson-Cook, C; Leach, NT, 2001
)
1.03
"Cytochalasin B-treated PMN were unable to kill either virulent or avirulent gonococci despite normal degranulation stimulated by the latter."( Gonococcal interactions with polymorphonuclear neutrophils: importance of the phagosome for bactericidal activity.
Densen, P; Mandell, GL, 1978
)
0.98
"Cytochalasin B-treated PMN's, incapable of ingesting particles but still able to bind particles to membrane receptors, generated enhanced amounts of O2- when treated with serum-treated zymosan (STZ), a C3b receptor stimulus, or with aggregated IgG (agg IgG), an Fc receptor stimulus."( Dissociation of phagocytosis, metabolic stimulation and lysosomal enzyme release in human leukocytes.
Goldstein, IM; Kaplan, HB; Roos, D; Weissmann, G, 1976
)
0.98
"Cytochalasin B-treated PMN were rounded, and in thin sections the retracted plasma membrane appeared as invaginations oriented toward centrally located centrioles."( Role of microtubule assembly in lysosomal enzyme secretion from human polymorphonuclear leukocytes. A reevaluation.
Goldstein, IM; Hoffstein, S; Weissmann, G, 1977
)
0.98
"Cytochalasin B-treated PMN exposed to C5a in calcium and magnesium-free media consistently secreted significant amounts of the granule-associated enzymes, beta-glucuronidase and lysozyme."( Influence of divalent cations upon complement-mediated enzyme release from human polymorphonuclear leukocytes.
Goldstein, IM; Hoffstein, ST; Weissmann, G, 1975
)
0.98
"Cytochalasin B-treatment prevented ridge formation and disrupted the bundles of microfilaments."( Morphogenesis of intestinal villi. II. Mechanism of formation of previllous ridges.
Burgess, DR, 1975
)
0.98
"Cytochalasin B treatment increased an IFN-alpha-induced membrane potential shift by -5 mV."( Cytoskeletal modulation of plasma membrane events induced by interferon-alpha.
Aszalos, A; Balint, E; Cheng, M; Grimley, PM; Rupp, B, 1992
)
1
"When cytochalasin B treatment was performed during the last syncytial mitoses many spindles fuse among them and the regular mitotic progression is perturbed."( Cytochalasin induces spindle fusion in the syncytial blastoderm of the early Drosophila embryo.
Callaini, G; Dallai, R; Riparbelli, MG, 1992
)
0.74
"Cytochalasin B (cyt B) pretreatment affected the production of O2- by exudate cells, although to a lesser extent than the production by peripheral blood cells, in which a substantial increase was induced."( Mechanisms in neutrophil priming: characterization of the oxidative response induced by formylmethionyl-leucyl-phenylalanine in human exudated cells.
Briheim, G; Dahlgren, C; Follin, P, 1991
)
1
"Cytochalasin B treatment, through its effect on actin polymerization, produced similar changes in cell shape and cytoskeletal actin."( Cell density-dependent decrease in cytoskeletal actin and myosin in cultured osteoblastic cells: correlation with cyclic AMP changes.
Egan, JJ; Gronowicz, G; Rodan, GA, 1991
)
1
"In cytochalasin B-treated, degranulating cells 30,000 to 50,000 receptors were up-regulated within a minute."( Kinetics of N-formyl peptide receptor up-regulation during stimulation in human neutrophils.
Eberle, M; Fay, SP; Lemke, HD; Norgauer, J; Sklar, LA, 1991
)
0.8
"Cytochalasin B treatment led to the formation of bi- and multinucleate cells, whose frequency increased with progressively longer incubation periods."( Fasciola hepatica: disruption of spermatogenesis by the microfilament inhibitor cytochalasin B.
Fairweather, I; Johnston, CF; Stitt, AW, 1991
)
1.23
"Cytochalasin B treatment of later stage embryos results in an uneven distribution of the antigen in cortical cytoplasm and prevents the complete removal of antigen from new sites of cell contact in multiple-embryo aggregates."( Establishment and maintenance of a regionalized glycoprotein distribution during early mouse development.
Calarco, PG; Pierce, KE, 1990
)
1
"Cytochalasin B treatment, as a control, reduced phagocytosis by approximately 70%."( Kinetics of phagocytosis in trabecular meshwork cells. Flow cytometry and morphometry.
Alvarado, JA; Bloom, E; Franse-Carman, L; Maglio, MT; Murphy, CG; Polansky, JR; Shirato, S, 1989
)
1
"Cytochalasin B treatment at early times of HCMV infection stimulated progeny virus production."( Cytoskeletal disruption during human cytomegalovirus infection of human lung fibroblasts.
Jones, NL; Kilpatrick, BA; Lewis, JC, 1986
)
0.99
"Cytochalasin B (CB) treatment, however, resulted in the enucleation of all cell types tested, even at a centrifugal force as low as 5,000 g."( Enucleation of phagocytic cells with adenine, guanine, and their nucleosides in combination with centrifugation.
Saito, T; Yamaguchi, J, 1988
)
1
"In cytochalasin B-treated Leydig cells, MA-01 antibody stained star-like structures that codistributed with actin patches and with a star-like arrangement of vimentin."( Cellular distribution of a protein related to neuronal microtubule-associated protein MAP-2 in Leydig cells.
Dráber, P; Dráberová, E; Viklický, V, 1986
)
0.78
"Cytochalasin B-treated mature eggs maintained intact meiotic spindles and exhibited a disappearance of microvillus-free areas and a reduction in cortical actin."( Development of cortical polarity in mouse eggs: involvement of the meiotic apparatus.
Chen, DY; Longo, FJ, 1985
)
0.99
"Cytochalasin B-treated leukocytes thus constitute a model system for quantitative study of lysosome fusion."( Cytochalasin B: effect on lysosomal enzyme release from human leukocytes.
Hoffstein, S; Weissmann, G; Zurier, RB, 1973
)
2.42
"Treatment with cytochalasin B in oocytes confirmed that SKAP2 was co-localized with actin."( SKAP2 regulates Arp2/3 complex for actin-mediated asymmetric cytokinesis by interacting with WAVE2 in mouse oocytes.
Chen, MH; Fu, BB; Fu, XP; He, SW; Hong, ZW; Li, FP; Liao, BQ; Lin, YH; Liu, Y; Liu, YX; Lui, R; Qi, ZQ; Wang, HL; Wang, YL; Xu, BH; Xu, L, 2017
)
0.79
"Treatment with cytochalasin B or the calcium chelator dibromo-BAPTA results in the disruption of all three of these actin-based structures, leading to the slowing or immediate arrest of epiboly, respectively, followed by a failure of yolk cell occlusion and the eventual lysis of the embryo through the vegetal pole region."( Organization and function of microfilaments during late epiboly in zebrafish embryos.
Cheng, JC; Miller, AL; Webb, SE, 2004
)
0.66
"Treatment with cytochalasin B decreased the second polar body extrusion rate of activated oocytes."( Optimization of Ca2+ concentrations in fusion and activation media for production of cloned embryos from miniature pig somatic cells.
Miyoshi, K; Yoshida, M; Yuki, Y, 2005
)
0.67
"Treatment with cytochalasin B (10(-5)-10(-4) M) caused a dose-dependent inhibition of acid secretion and a concomitant gradient of morphologic alteration of oxyntic cells."( The effects of microfilament disrupting agents on HCl secretion and ultrastructure of piglet gastric oxyntic cells.
Black, JA; Forte, JG; Forte, TM, 1982
)
0.6
"Pretreatment by cytochalasin B produced a marked decrease in STZ-stimulated production of reactive oxygen species."( Reactive oxygen production by cultured rat glomerular mesangial cells during phagocytosis is associated with stimulation of lipoxygenase activity.
Ardaillou, R; Baud, L; Hagege, J; Perez, J; Rondeau, E; Sraer, J, 1983
)
0.6
"Treatment with cytochalasin B (15 micrograms/ml) and/or colchicine (100 microM) does not alter the restricted mobility of surface components seen on differentiated cells."( Changes in cell surface antigens during in vitro lizard myogenesis.
Marusich, MF; Simpson, SB, 1983
)
0.61
"Treatment with cytochalasin B or colchicine does not stop this embryonic tissue movement, suggesting that the muscle is the main motive force in corneal closure."( Closure of the squid cornea: a muscular basis for embryonic tissue movement.
Arnold, JM, 1984
)
0.61
"NHEK treated with cytochalasin B or D to inhibit actin polymerization exhibited a diffuse ODC localization that could be reversed by removal of the cytochalasin; inhibition of ODC by alpha-difluoromethylornithine caused a diffuse ODC localization."( Relationship between ornithine decarboxylase and cytoskeletal organization in cultured human keratinocytes: cellular responses to phorbol esters, cytochalasins, and alpha-difluoromethylornithine.
Hickok, NJ; Jänne, OA; Pomidor, MM; Ruhl, KK; Song, Y; Tuan, RS; Zheng, P, 1995
)
0.61
"Treatment with cytochalasin B in culture and incubation at 4 degrees C resulted in strongly labeled plasma membrane and inhibition of internalization."( Endocytosis of integrin alpha 5 beta 1 (fibronectin receptor) of mouse peritoneal macrophages in vitro: an immunoelectron microscopic study.
Scheller, M; Shakibaei, M; Zimmermann, B,
)
0.47
"Pretreatment with cytochalasin B or colchicine decreased D to (3.64 +/- 0.29) x 10(-9) cm2/s (P < 0.003) and (3.96 +/- 0.18) x 10(-9) cm2/s (P < 0.013) respectively."( Rapid alterations in lateral mobility of lipids in the plasma membrane of activated human megakaryocytes.
Akkerman, JW; de Laat, SW; Gorter, G; Schootemeijer, A; Tertoolen, LG; van Beekhuizen, AE, 1994
)
0.61
"Pretreatment with cytochalasin B, which is known to disrupt microfilaments, significantly inhibits regulatory volume decrease (RVD) in Ehrlich ascites tumor cells, suggesting that an intact microfilament network is a prerequisite for a normal RVD response. "( Relation between cytoskeleton, hypo-osmotic treatment and volume regulation in Ehrlich ascites tumor cells.
Cornet, M; Hoffmann, EK; Lambert, IH, 1993
)
0.62
"Treatment with cytochalasin B inhibited microfilament polymerisation and prevented movement of cortical granules to the cortex."( Microfilament assembly and cortical granule distribution during maturation, parthenogenetic activation and fertilisation in the porcine oocyte.
Chung, KS; Day, BN; Kim, NH; Lee, HT, 1996
)
0.63
"Pretreatment with cytochalasin B prevented the accumulation of cadherins-catenins and ZO-1 at the sites of apoptosis and resulted in microscopic holes in the TNF-treated cell sheet."( Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells.
Knudsen, KA; Marano, CW; Mullin, JM; Peralta Soler, A, 1996
)
0.62
"Treatment with cytochalasin B also resulted in a dose-dependent decrease in cell area."( Characterization of focal adhesion assembly in XR1 glial cells.
Folsom, TD; Sakaguchi, DS, 1997
)
0.64
"Treatment with cytochalasin B inhibited microfilament polymerisation but did not prevent either germinal vesicle breakdown or metaphase formation."( The distribution and requirements of microtubules and microfilaments in bovine oocytes during in vitro maturation.
Cho, SK; Choi, SH; Kim, EY; Kim, NH; Lim, JH; Park, SP, 2000
)
0.65
"Treatment with cytochalasin B in a concentration of 30mug/ml leads to loss of locomotion."( Motility of l5222 rat leukemia cells.
Felix, H; Haemmerli, G; Sträuli, P, 1976
)
0.6
"Pretreatment with cytochalasin B did not enhance IP3 synthesis."( Changes in inositol 1,4,5-trisphosphate mass in agonist-stimulated human neutrophils.
Ernest, MJ; Fruman, DA; Gamache, DA, 1991
)
0.6
"Treatment with cytochalasin B caused microridges to disappear or to become thinner and lower or to change short or microvillus-like microridges."( Cytoskeleton in microridges of the oral mucosal epithelium in the carp, Cyprinus carpio.
Miyoshi, M; Miyoshi, S; Uehara, K, 1991
)
0.62
"Treatment with cytochalasin B (CB) before first cleavage prevents the formation of the polar lobe and leads to equal cleavage and the equal distribution of lobe material."( Development of Iiyanassa obsoleta embryos after equal distribution of polar lobe material at first cleavage.
Render, J, 1989
)
0.62
"Pretreatment with cytochalasin B virtually prevented endocytosis of SCG particles, indicating active participation of the cytoskeleton."( Endocytosis by cultured mesangial cells and associated changes in prostaglandin E2 synthesis.
DeCandido, S; Ding, GH; Franki, N; Hays, RM; Schlondorff, D; Singhal, PC, 1987
)
0.6
"Treatment with cytochalasin B, cytochalasin D and lead acetate, compounds that interfere with microfilament related processes, re-organized the microfilaments into abnormal crossed and highly condensed masses."( Effects of microfilament disrupters on microfilament distribution and morphology in maize root cells.
Vaughan, MA; Vaughn, KC, 1987
)
0.61
"Treatment with cytochalasin B led to no significant change in the mean diameter of the fenestrae but to an increase in their number and in the porosity of the cells (percentage of the cellular surface opened by the fenestrae) which attained up to 300% of that of the controls."( Increase in the number of fenestrae in mouse endothelial liver cells by altering the cytoskeleton with cytochalasin B.
Gendrault, JL; Kirn, A; Steffan, AM,
)
0.69
"Treatment with cytochalasin B modulates functional activity so that all cells depolarize or reduce nitroblue tetrazolium in response to this chemoattractant, but the heterogeneous binding of 31D8 does not change."( An antibody binding to human neutrophils demonstrates antigenic heterogeneity detected early in myeloid maturation which correlates with functional heterogeneity of mature neutrophils.
Gallin, JI; Malech, HL; Melnick, DA; Seligmann, B, 1985
)
0.61
"6. Treatment with cytochalasin B at doses of up to 10mug/ml for as long as 72h did not significantly change the total activities of any of the enzymes measured."( Selective release of lysosomal hydrolases from phagocytic cells by cytochalasin B.
Allison, AC; Davies, P; Haswell, AD, 1973
)
0.81

Toxicity

ExcerptReferenceRelevance
" The microtubule-disruptive agents colchicine (10-4 M), vinblastine (10-5 M) and colcemid (10-6 M) did not influence antibody-dependent cytotoxicity at concentrations which were not toxic to the effector cells."( Antibody-dependent cytotoxicity: modulation by the cytochalasins and microtubule-disruptive agents.
Gelfand, EW; Morris, SA; Resch, K, 1975
)
0.25
"The role of lysosomal enzyme released by macrophages was examined in relation to the toxic effect caused by food yeast."( Lysosomal enzyme release from macrophages: a model of food yeast toxicity evaluation.
Hernández Rosales, F; Illnait, J; Sarracent, J; Zayas, M, 1988
)
0.27
" Perturbation of cytophilic IgG with particle-bound protein A elicited a chemiluminescent response from peritoneal macrophages; however, experiments with scavengers of reactive oxygen species indicated that toxic oxygen radicals may not be required for cytotoxicity."( Human peritoneal macrophage cytotoxicity mediated by cytophilic IgG.
Freiberg, M; Keane, WF; Miller, W; Peterson, PK; Staub, D; Verbrugh, HA, 1983
)
0.27
" Underestimation of toxicity may lead to inappropriately toxic concentrations being selected for analysis, with the potential for generation of irrelevant positive results."( Comparison of different methods for an accurate assessment of cytotoxicity in the in vitro micronucleus test. II: Practical aspects with toxic agents.
Fellows, MD; Kirkland, D; Lorge, E; O'Donovan, MR,
)
0.13
"Copper oxide nanoparticles (CuO NPs) are used for their biocide potential however they were also shown to be highly toxic to mammalian cells."( Genotoxic effects of copper oxide nanoparticles in Neuro 2A cell cultures.
de Oliveira Franco Rossetto, AL; Gerson Matias, W; Henning da Costa, C; Pedroso Melegari, S; Perreault, F; Popovic, R, 2012
)
0.38
"Skeletal muscle-associated toxicity is an underresearched area in the field of high-throughput toxicity screening; hence, the potential adverse effects of drugs and chemicals on skeletal muscle are largely unknown."( High-Content Assay Multiplexing for Muscle Toxicity Screening in Human-Induced Pluripotent Stem Cell-Derived Skeletal Myoblasts.
Klaren, WD; Rusyn, I,
)
0.13

Compound-Compound Interactions

Anti-immunoglobulin in combination with cytochalasin B stimulated substantial proliferation as judged by [3H]thymidine incorporation. Most studies of mouse cloning successfully achieved activation of the reconstructed oocytes by strontium (Sr) combined with cy tochalasinB (CB) treatment.

ExcerptReferenceRelevance
" However, anti-immunoglobulin in combination with cytochalasin B stimulated substantial proliferation as judged by [3H]thymidine incorporation."( Anti-immunoglobulin in combination with cytochalasin stimulates proliferation of murine B lymphocytes.
Rothstein, TL, 1985
)
0.52
"Anticonvulsant effect of cytoskeletal depolymerizing drugs in combination with potassium channel (KATP) opener and adenylate cyclase activator was evaluated in animal models of epilepsy."( Anticonvulsant effect of cytoskeletal depolymerizers in combination with potassium channel opener and adenylate cyclase activator; a causative link with nerve growth factor?
Jose, VM; Tyagi, MG, 2001
)
0.31
"Most studies of mouse cloning successfully achieved activation of the reconstructed oocytes by strontium (Sr) combined with cytochalasin B (CB) treatment."( Transgenic cloned mice expressing enhanced green fluorescent protein generated by activation stimuli combined with 6-dimethylaminopurine.
Chen, CH; Ju, JC; Lee, KH; Lien, WT; Liu, MS; Stone, L; Tu, CF, 2008
)
0.55
" In contrast, TERT expression combined with β-HPV 8E6 expression allowed cells to proliferate for months following cytokinesis failure."( β-HPV 8E6 combined with TERT expression promotes long-term proliferation and genome instability after cytokinesis failure.
Dacus, D; Riforgiate, E; Wallace, NA, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The experiments were performed on peripheral blood from 20 healthy donors, and several conditions were tested by varying the duration of exposure, the specific absorption rate (SAR), and the signal [continuous-wave (CW) or GSM (Global System of Mobile Communication) modulated signal]."( Lack of genotoxic effects (micronucleus induction) in human lymphocytes exposed in vitro to 900 MHz electromagnetic fields.
Antolini, A; Bersani, F; Chiavoni, AS; Forigo, D; Sannino, A; Scarfì, MR; Zeni, O, 2003
)
0.32

Dosage Studied

The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine. In order to optimize the experimental protocol for the use of cytokinesis-blocked lymphocytes in aneuploidy assays, the effect of harvest time and cyto Chalasin B (Cyt B) dosage upon chromosome distribution was investigated.

ExcerptRelevanceReference
"The dose-response effects of phorbol myristate acetate and cytochalasin B on secretion of azurophil and specific granule enzymes from viable human polymorphonuclear leukocytes have been examined."( Cytochalasin B-dependent release of azurophil granule enzymes from human polymorphonuclear leukocytes.
Yurewicz, EC; Zimmerman, M, 1977
)
1.94
" Comparison of PMN and macrophages from different species showed that the maximal chemiluminescent response seen in the dose-response curve of F-Met- Phe was different in different cell types."( Chemiluminescence of phagocytic cells caused by N-formylmethionyl peptides.
Gardner, DE; Hatch, GE; Menzel, DB, 1978
)
0.26
" All forms of IL-8 stimulated PIP kinase activity in concentrations ranging from 1 to 50 nM, and the dose-response curves exactly correlated with the order of potency of these cytokines for interacting with the IL-8R on the surface of neutrophils."( IL-8 stimulates phosphatidylinositol-4-phosphate kinase in human polymorphonuclear leukocytes.
Costello, KM; Lamb, KA; Pike, MC, 1992
)
0.28
" The effects of dosage (2."( Parthenogenetic development of bovine oocytes treated with ethanol and cytochalasin B after in vitro maturation.
Fukui, Y; Furudate, M; Iwazumi, Y; Ohsaki, K; Sato, N; Sawai, K, 1992
)
0.52
" Dose-response studies performed on blood from normal healthy volunteers showed higher maximal secretory responses in males than females (33."( Assessment of neutrophil leukocyte secretory response to fMLP in whole blood in vitro.
Butt, TJ; Chadwick, VS; Ferry, DM, 1992
)
0.28
" Blood from both groups was irradiated in vitro for the study of the dose-response relationship."( Micronuclei in human lymphocytes irradiated in vitro or in vivo.
Gantenberg, HW; Müller, WU; Streffer, C; Wuttke, K, 1991
)
0.28
" Hyposmotic stress during added verapamil dosage (50 mumol/L) also resulted in 23% greater cell swelling compared with control."( Involvement of cell calcium and transmembrane potential in control of hepatocyte volume.
Khalbuss, WE; Wondergem, R, 1991
)
0.28
" Dose-response studies, also reported here, indicate that the detergent insolubility of the complexes does not correlate with secretion."( Antigen-dependent transition of IgE to a detergent-insoluble form is associated with reduced IgE receptor-dependent secretion from RBL-2H3 mast cells.
Oliver, JM; Seagrave, J, 1990
)
0.28
" Time-course and dose-response studies of CB treatment showed lattice formation to follow disruption of stress fibers and the concentration of actin into distinct patches that marked the location of lattice foci."( Cytochalasin B-induced redistribution of cytokeratin filaments in PtK1 cells.
Mullins, JM; Wolf, KM, 1987
)
1.72
" The insulin dose-response curve of the metabolic clearance rate (MCR) of glucose revealed a decrease of the maximal response without a rightward shift in STZ rats."( Postreceptor defect in insulin action in streptozotocin-induced diabetic rats.
Imura, H; Inoue, G; Kakehi, T; Kono, S; Kosaki, A; Kuzuya, H; Nishimura, H; Okamoto, M; Yamada, K, 1989
)
0.28
" When dose-response parameters were compared with those for total acentrics scored in first division metaphases, we observed no significant differences in estimates of the background (gamma) or linear (alpha) coefficients, but a 2-fold reduction in the beta coefficient for MN."( Comparisons of dose-response parameters for radiation-induced acentric fragments and micronuclei observed in cytokinesis-arrested lymphocytes.
Frome, EL; Littlefield, LG; Sayer, AM, 1989
)
0.28
" The dose-response curves for the effects of cytochalasin B on pinocytosis and Na+ content were identical."( Effects of cytochalasin B on Na+ content and cell volume of Entamoeba histolytica.
Bakker-Grunwald, T; Löhden, U; Trissl, D, 1985
)
0.92
" The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine and by the capacity of the FMLP receptor antagonist carbobenzoxyphenylalanyl-methionine to inhibit the agonist action of FMLP in a dose-response fashion."( Generation of leukotrienes by human monocytes pretreated with cytochalasin B and stimulated with formyl-methionyl-leucyl-phenylalanine.
Austen, KF; Lee, TH; Lewis, RA; Robin, JL; Williams, JD, 1986
)
0.73
" The consistent dose-response relations were obtained in cultures treated with mitomycin C, caffeine and colcemid."( Measurement of micronuclei by cytokinesis-block method in cultured Chinese hamster cells: comparison with types and rates of chromosome aberrations.
Sasaki, MS; Wakata, A, 1987
)
0.27
"6% at the lowest dosage (0."( Spontaneous expulsion of micronuclei by enucleation in the micronucleus assay.
Ariyuki, F; Nito, S; Okaniwa, A,
)
0.13
" In addition, PhAsO is shown to inhibit cytochalasin B binding to plasma membranes from insulin-stimulated adipocytes in a concentration-dependent manner which parallels the dose-response inhibition of hexose transport by PhAsO."( Direct interaction of phenylarsine oxide with hexose transporters in isolated rat adipocytes.
Douen, AG; Jones, MN; Kacem, R, 1988
)
0.54
" Dose-response studies of GS-Mal treatment of intact cells suggested that some functional carriers lack a reactive external sulfhydryl, which can be partially regenerated by pretreatment with excess cysteine."( Reaction of an exofacial sulfhydryl group on the erythrocyte hexose carrier with an impermeant maleimide. Relevance to the mechanism of hexose transport.
May, JM, 1988
)
0.27
" A series of dose-response studies were performed, and correlated with exposure time."( Colchicine reverts cell shape but not collagen phenotypes in corneal endothelial cells modulated by polymorphonuclear leukocytes.
Kay, EP; Oh, S, 1987
)
0.27
" The results indicated that the dose-response was linear and a single in vitro exposure to 5 rad of X-rays could be unequivocally detected."( Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo ageing and low dose X-irradiation.
Fenech, M; Morley, AA, 1986
)
0.27
" Inhibition of phagocytosis and changes in cell shape by cytochalasin B exhibited nearly identical dose-response curves requiring 2-5 x 10(-6) M and 1-2 x 10(-5) M cytochalasin B to inhibit these functions by 50% and 100%, respectively."( Inhibition of phagocytosis and plasma membrane mobility of the cultivated macrophage by cytochalasin B. Role of subplasmalemmal microfilaments.
Axline, SG; Reaven, EP, 1974
)
0.72
" From these results, we conclude that (1) the ordering effect of insulin addition to isolated liver plasma membrane fractions occurs within the physiological range of hormone concentration, and the dose-response is right-shifted in membranes from 'insulin resistant' animals; (2) the relative responses of the fluorescent and spin probes suggest that the effects of insulin are confined to specific domains within the membrane matrix; and (3) the direct effects of insulin on the membranes may involve protein components having cytochalasin B binding sites."( Effects of insulin on the lipid structure of liver plasma membrane measured with fluorescence and ESR spectroscopic methods.
Hyslop, PA; Sauerheber, RD; York, DA, 1984
)
0.43
" Furthermore, CB converted the biphasic dose-response curve for CCK8-induced amylase release to a monophasic shape, such that the amylase release stimulated by a high concentration of CCK8 (10 nM) was augmented."( Effects of high concentrations of secretagogues on the morphology and secretory activity of the pancreas: a role for microfilaments.
Burnham, DB; Williams, JA, 1982
)
0.26
" In all tests, the qualitative nature of the dose-response curve was not altered by NH4Cl treatment."( Interferon induction by viruses. XI. Early events in the induction process.
Marcus, PI; Svitlik, C, 1984
)
0.27
" Kinetic and dose-response studies showed that PGBX mimicked te action of ionophore A23187 in PMN."( PGBX, a prostagandin derivative, mimics the action of the calcium ionophore A23187 on human neutrophils.
Korchak, HM; Serhan, CN; Weissmann, G, 1980
)
0.26
" Finally, in a dosage which blocked degranulation, verapamil inhibited calcium uptake."( Role of extracellular calcium and neutrophil degranulation responses to 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine.
Lees, CJ; McCall, CE; O'Flaherty, JT; Swendsen, CL, 1981
)
0.26
" Neither the time course of the response nor the dose-response curve is affected by the removal of calcium from the suspending medium."( Stimulation by chemotactic factor of actin association with the cytoskeleton in rabbit neutrophils. Effects of calcium and cytochalasin B.
Naccache, PH; Sha'afi, RI; White, JR, 1983
)
0.47
" The dose-response curve was similar to that obtained by 3H-thymidine assay."( Early changes in concanavalin A-stimulated lymphocytes detected by the fluorescent probe N-phenyl-1-naphthylamine.
Betts, RL; Halliday, GM; Hocking, GR; Nairn, RC; Rolland, JM, 1981
)
0.26
" The enchancement of killing by pretreatment with cell wall-active antibiotics was present in a dose-response fashion to 1/16th the MIC."( Interactions between antibiotics and human neutrophils in the killing of staphylococci.
Isturiz, R; Malech, HL; Metcalf, JA; Molavi, A; Root, RK, 1981
)
0.26
" A linear dose-response was observed between induced damage expressed as the frequency of micronuclei and radiation dose in all but one melanoma (V39) cell line."( The micronucleus assay: an evaluation of its use in determining radiosensitivity in vitro.
Champion, AR; Court, JB; Hanson, JA; Venables, SE, 1995
)
0.29
"Using the cytokinesis-block technique, lymphocytes from healthy volunteers (n = 9) were evaluated for 1) the radiation dose-response curve for micronuclei (MN) expression; 2) technique variables on the yield of MN; and 3) the shortest lymphocyte incubation time required for the MN assay."( Radiation dose-dependent variations of micronuclei production in cytochalasin B-blocked human lymphocytes.
Blackburn, LD; Esinhart, JD; Lee, TK; Wiley, AL, 1994
)
0.53
" In order to optimize the experimental protocol for the use of cytokinesis-blocked lymphocytes in aneuploidy assays, the effect of harvest time and cytochalasin B (Cyt B) dosage upon chromosome distribution was investigated."( Simultaneous detection of X-chromosome loss and non-disjunction in cytokinesis-blocked human lymphocytes by in situ hybridization with a centromeric DNA probe; implications for the human lymphocyte in vitro micronucleus assay using cytochalasin B.
Crebelli, R; Leopardi, P; Marcon, F; Zijno, A, 1994
)
0.67
" In HIT cells the abnormal glucose transport mechanism is associated with a marked shift to the left of the glucose-induced insulin release dose-response curve."( Inhibition of the high-affinity glucose transporter GLUT 1 affects the sensitivity to glucose in a hamster-derived pancreatic beta cell line (HIT).
Anello, M; Buscema, M; Caltabiano, V; Purrello, F; Rabuazzo, AM; Vigneri, R; Vinci, C, 1993
)
0.29
" In dose-response experiments, pathfinding became abnormal in the same concentration range in which filopodia disappeared."( Navigational errors made by growth cones without filopodia in the embryonic Xenopus brain.
Chien, CB; Harris, WA; Holt, CE; Rosenthal, DE, 1993
)
0.29
" In 9/11 lines the PFU dose-response curves were exponential, while in two there was a pronounced curvature (quadratic parameter)."( Prediction of the initial slope of the acute clonogenic survival curve by the post-irradiation behaviour of cytochalasin-induced polykaryons.
Burn, C; Court, JB; Davies, HE, 1995
)
0.29
" Dose-response curves (DRCs) to the pigment-concentrating hormone PCH were determined under control and experimental conditions to evaluate the effects elicited by the cytoskeleton-affecting drugs."( Cytoskeleton and PCH-induced pigment aggregation in Macrobrachium potiuna erythrophores.
Castrucci, AM; Josefsson, L; Tuma, MC, 1995
)
0.29
" This vinblastine dosage had a severe inhibitory effect on cultures treated with Cyt B, where no binucleated cells were detected."( Analysis of chromosome segregation by means of fluorescence in situ hybridization: application to cytokinesis-blocked human lymphocytes.
Crebelli, R; Leopardi, P; Marcon, F; Zijno, A, 1996
)
0.29
" Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases."( The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro.
Fisher, EA; Fuki, IV; Iozzo, RV; Kuhn, KM; Lomazov, IR; Rothman, VL; Swenson, TL; Tuszynski, GP; Williams, KJ, 1997
)
0.49
"Previous failures in the pharmacologic prevention of restenosis may have been related to inadequate dosing at the angioplasty site as a result of systemic drug administration."( Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans.
Lansky, AJ; Lehmann, KG; Popma, JJ; Werner, JA; Wilensky, RL, 2000
)
0.57
"The polykaryon-forming unit (PFU) assay measures the survival of multiple cycles of DNA synthesis after exposure to ionizing radiation, and it is known that there is a strong correlation between the slope of the PFU dose-response curve and the clonogenic initial slope."( Correlation between the clonogenic initial slope and the response of polykaryon-forming units: the behavior of strains defective in XRCC5 and ATM and the heritability of small variations in radioresponse.
Bowen, ID; Court, JB; Davies, HE; Manti, L; Venables, S, 2000
)
0.31
" Comparison of meiosis I triploids, meiosis II triploids and diploid siblings established that improved physiological performance in triploids was associated with increased allelic variation, rather than with the quantitative dosage effects of ploidy status."( Separate effects of triploidy, parentage and genomic diversity upon feeding behaviour, metabolic efficiency and net energy balance in the Pacific oyster Crassostrea gigas.
Bougrier, S; Day, AJ; Hawkins, AJ; Héral, M; Kotoulas, G; Magoulas, A; Naciri-Graven, Y, 2000
)
0.31
" To evaluate the results we used the reproducibility of counts, established a dose-response curve for gamma-irradiation and used the ability of the system to differentiate between breast cancer patients and controls as a biological reference, a difference which we had observed before by visual counting."( An automated scoring procedure for the micronucleus test by image analysis.
Jainta, S; Johannes, T; Kiechle, M; Patino Garcia, B; Schuster, S; Schwarz-Boeger, U; Varga, D; Vogel, W, 2004
)
0.32
" Intravitreal injection of cytochalasin B inhibited NF axonal transport in optic axons in a dose-response manner."( Neurofilament transport is dependent on actin and myosin.
Chylinski, TM; Jung, C; Ortiz, D; Pimenta, A; Shea, TB, 2004
)
0.62
" In order to assess extensive dose-response relationships, we selected expected weak (diazepam, phenolphthalein, quinacrine dihydrochloride dihydrate) and strong (cytosine arabinoside, mitomycin C, vinblastine sulphate) inducers of micronuclei with a variety of different mechanisms of action for testing."( Evaluation of phenolphthalein, diazepam and quinacrine dihydrochloride in the in vitro mammalian cell micronucleus test in Chinese hamster ovary (CHO) and TK6 cells.
Cheung, J; Colman, M; Dickinson, D; Engel, M; Gudi, R; Kumar, S; Maduka, N; Schuler, M; Sherman, J; Szkudlinska, A; Thiffeault, C, 2010
)
0.36
" ITMC is a valuable tool to monitor the biological responses to nano-sized dosage forms such as NPs."( Microcalorimetric method to assess phagocytosis: macrophage-nanoparticle interactions.
Al-Hallak, MH; Azarmi, S; Kohan, MH; Löbenberg, R; Roa, WH; Sarfraz, MK, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
mycotoxinPoisonous substance produced by fungi.
actin polymerisation inhibitorAny substance that inhibits the polymerisation of the protein actin.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
cytochalasin
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
lactoneAny cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Drug induction of bile acid pathway025

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency60.45660.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency0.94480.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency63.09570.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency1.12200.00527.809829.0929AID588855
PINK1Homo sapiens (human)Potency5.62342.818418.895944.6684AID624263
67.9K proteinVaccinia virusPotency5.01190.00018.4406100.0000AID720579
ParkinHomo sapiens (human)Potency5.62340.819914.830644.6684AID624263
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency100.00000.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency1.29950.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency1.12200.01262.451825.0177AID485313
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency4.55300.00419.984825.9290AID504444
mitogen-activated protein kinase 1Homo sapiens (human)Potency8.91250.039816.784239.8107AID1454
ras-related protein Rab-9AHomo sapiens (human)Potency6.30960.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency19.95260.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency5.20780.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency11.22020.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.63100.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
neutrophil cytosol factor 1Homo sapiens (human)IC50 (µMol)50.00000.39006.544129.1200AID1275
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)4.10000.00492.99549.9920AID1794830
Solute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)IC50 (µMol)3.90003.90003.90003.9000AID1794827
Solute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)IC50 (µMol)3.90002.50003.20003.9000AID1794828
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (37)

Processvia Protein(s)Taxonomy
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
fructose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
carbohydrate metabolic processSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
galactose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
learning or memorySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
positive regulation of brain-derived neurotrophic factor receptor signaling pathwaySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose homeostasisSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
short-term memorySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
long-term memorySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
carbohydrate metabolic processSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
amylopectin biosynthetic processSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to insulin stimulusSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose homeostasisSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose import in response to insulin stimulusSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
response to ethanolSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
brown fat cell differentiationSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
white fat cell proliferationSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to tumor necrosis factorSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to osmotic stressSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
regulation of synaptic vesicle budding from presynaptic endocytic zone membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
fructose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
galactose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
glucose bindingSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose uniporter activitySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
aggresomeSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
secretory granule membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
specific granule membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
cell projectionSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
perikaryonSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
tertiary granule membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
ficolin-1-rich granule membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 3Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
multivesicular bodySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
trans-Golgi networkSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
clathrin-coated pitSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
external side of plasma membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
endomembrane systemSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
vesicle membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
sarcoplasmic reticulumSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
clathrin-coated vesicleSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
trans-Golgi network transport vesicleSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
T-tubuleSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cytoplasmic vesicle membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
insulin-responsive compartmentSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
membrane raftSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
perinuclear region of cytoplasmSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
endomembrane systemSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
perinuclear region of cytoplasmSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (137)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1782562Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID401579Inhibition of LFA1/ICAM1-mediated HL60 cell aggregation2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID354538Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID1091234Herbicidal activity against Sonchus arvensis (field sow-thistle) assessed as induction of leaf necrotic lesions measured 24 hr post compound treatment by leaf disk- puncture bioassay2008Journal of agricultural and food chemistry, Aug-13, Volume: 56, Issue:15
Production of phytotoxins by Phoma exigua var. exigua, a potential mycoherbicide against perennial thistles.
AID324484Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID657282Cytotoxicity against human A549 cells after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Cytotoxic cytochalasins from the endozoic fungus Phoma sp. of the giant jellyfish Nemopilema nomurai.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID657287Cytotoxicity against human HeLa cells after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Cytotoxic cytochalasins from the endozoic fungus Phoma sp. of the giant jellyfish Nemopilema nomurai.
AID401584Specific index, ratio of IC50 for CHO cells to IC50 for LFA1/ICAM12004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID360015Inhibition of LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells after 45 mins by fluorescence analysis2001Journal of natural products, May, Volume: 64, Issue:5
Antimalarial, cytotoxic, and antifungal alkaloids from Duguetia hadrantha.
AID409947Inhibition of human recombinant MAOB at 1 mM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID356103Cytotoxicity against human HL60 cells by XTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Antiparasitic alkaloids from Psychotria klugii.
AID409952Inhibition of human brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID360012Inhibition of LFA1/ICAM1-mediated aggregation of TPA-stimulated human HL60 cells pretreated 10 mins before TPA challenge measured after 16 hrs of PMA addition by microscopy2001Journal of natural products, May, Volume: 64, Issue:5
Antimalarial, cytotoxic, and antifungal alkaloids from Duguetia hadrantha.
AID401580Cytotoxicity against human HL60 cells by XTT assay2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID337991Inhibition of actin polymerization in fMLP-stimulated human neutrophils assessed as positive fluorescence signal at 1 uM1994Journal of natural products, Nov, Volume: 57, Issue:11
Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID401563Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID657284Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Cytotoxic cytochalasins from the endozoic fungus Phoma sp. of the giant jellyfish Nemopilema nomurai.
AID657286Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Cytotoxic cytochalasins from the endozoic fungus Phoma sp. of the giant jellyfish Nemopilema nomurai.
AID1693699Antimigratory activity against human MDA-MB-231 cells assessed as minimum effective concentration by light microscopy2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID337990Inhibition of actin polymerization in fMLP-stimulated human neutrophils assessed as positive fluorescence signal at 10 uM1994Journal of natural products, Nov, Volume: 57, Issue:11
Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID324380Induction of light chain 3-GFP level in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID356106Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis2003Journal of natural products, Jul, Volume: 66, Issue:7
Antiparasitic alkaloids from Psychotria klugii.
AID356107Specific index, ratio of IC50 for human HL60 cells to MIC for LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells2003Journal of natural products, Jul, Volume: 66, Issue:7
Antiparasitic alkaloids from Psychotria klugii.
AID1693690Inhibition of rabbit muscle G-actin polymerization assessed as polymerized G-actin level at 25 uM incubated for 15 mins by spectrophotometric analysis (Rvb = 100 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID45400Effect on cross resistance of CHO cells resistant to colchicine (CHRC5)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID409950Inhibition of human brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID360013Cytotoxicity against human HL60 cells after 7 days by XTT/PMS assay2001Journal of natural products, May, Volume: 64, Issue:5
Antimalarial, cytotoxic, and antifungal alkaloids from Duguetia hadrantha.
AID354543Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID657285Cytotoxicity against human XF498 cells after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Cytotoxic cytochalasins from the endozoic fungus Phoma sp. of the giant jellyfish Nemopilema nomurai.
AID401586Specific index, ratio of IC50 for mouse RAW264.7 to IC50 for iNOS production in mouse RAW264.72004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID356105Specific index, ratio of IC50 for human HL60 cells to MIC for LFA1:CD11a/CD18/ICAM1- mediated aggregation in PMA-induced human HL60 cells2003Journal of natural products, Jul, Volume: 66, Issue:7
Antiparasitic alkaloids from Psychotria klugii.
AID657288Induction of mitochondrial apoptosis in human HeLa cells2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Cytotoxic cytochalasins from the endozoic fungus Phoma sp. of the giant jellyfish Nemopilema nomurai.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID401581Specific index, ratio of IC50 for human HL60 cells to MIC for LFA1/ICAM12004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID324432Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID401585Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID1693700Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 4 hrs by neutral red uptake assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID1693697Antimigratory activity against human MDA-MB-231 cells assessed as cell migration at 10 uM by light microscopy relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID360016Specific index, ratio of IC50 for human HL60 cells to IC50 for LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells2001Journal of natural products, May, Volume: 64, Issue:5
Antimalarial, cytotoxic, and antifungal alkaloids from Duguetia hadrantha.
AID1782561Antibacterial activity against Vibrio parahaemolyticus QDIO-8 assessed as reduction in microbial growth by microtiter plate reader assay
AID356104Inhibition of LFA1:CD11a/CD18/ICAM1- mediated aggregation in PMA-induced human HL60 cells2003Journal of natural products, Jul, Volume: 66, Issue:7
Antiparasitic alkaloids from Psychotria klugii.
AID401582Inhibition of LFA1/ICAM1-mediated adhesion of HL60 cells to CHO-ICAM1 cells2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID360014Specific index, ratio of IC50 for human HL60 cells to MIC for LFA1/ICAM1 mediated aggregation in TPA-stimulated human HL60 cells2001Journal of natural products, May, Volume: 64, Issue:5
Antimalarial, cytotoxic, and antifungal alkaloids from Duguetia hadrantha.
AID657283Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Cytotoxic cytochalasins from the endozoic fungus Phoma sp. of the giant jellyfish Nemopilema nomurai.
AID1693248Inhibition of GLUT in human HepG2 cells assessed as inhibition of 2-NBDG uptake at 10 uM incubated for 20 mins by fluorescence microplate reader2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect.
AID1693688Inhibition of rabbit muscle F-actin depolymerization at 50 to 100 uM incubated for 15 mins by spectrophotometric analysis2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID1693694Induction of cell morphological changes in human MDA-MB-231 cells assessed as membrane blebbing at 500 nM measured after 40 sec by inverted microscopy2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID401583Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID1782564Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID521884Induction of depolymerization of actin microfilaments in african green monkey Vero cells at 25 uM after 30 mins by immunofluorescence method2009Nature chemical biology, Mar, Volume: 5, Issue:3
Golgicide A reveals essential roles for GBF1 in Golgi assembly and function.
AID1693701Cardiotoxicity in medaka embryo post hatching 24 hrs assessed as reduction in heart beat at 10 uM measured after 1 hr2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID354542Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID324536Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1091233Herbicidal activity against Cirsium arvense (Canada thistle) assessed as induction of leaf necrotic lesions measured 24 hr post compound treatment by leaf disk- puncture bioassay2008Journal of agricultural and food chemistry, Aug-13, Volume: 56, Issue:15
Production of phytotoxins by Phoma exigua var. exigua, a potential mycoherbicide against perennial thistles.
AID1782563Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1436775Inhibition of GLUT in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of choline buffer measured after 1 hr by resazurin dye based fluorescence assay2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID1436782Inhibition of GLUT in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID405970Effect on morphology in human A498 cells assessed as appearance of binucleated cells after 16 hrs by microfilament immunofluorescence assay2008Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13
Synthetic and pharmacological studies on new simplified analogues of the potent actin-targeting Jaspamide.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347354UWB1.289-WTBRCA1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347402qHTS for inhibitors of Rabies Virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347347UWB1.289 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347358HPAF-II 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347396qHTS for inhibitors of Wild type Zika virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347392qHTS for activators of dead-cell proteases activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347351U-118MG Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347352COV-362 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347369MCF7 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347401Redox Reaction Profiling qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347373qHTS for Constitutive Androstane Receptor (CAR) Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347360HPAF-II 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347368G06 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID134737610-beta competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347372qHTS for Constitutive Androstane Receptor (CAR) Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347363Firefly luciferase counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347348OV-SAHO Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347381Inflammasome Signaling qHTS Counterscreen: IL-1-beta AlphaLISA counterscreen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347380qHTS for Antimalaria activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347355HEK-293 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347393qHTS for inhibitors of ER calcium dysfunction: SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347350SW1088 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347388qHTS for Activators of p53 Stress Response Pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347370qHTS for ATAD5 Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347387Cytotoxicity qHTS for assessment of Hepg2 cells membrane integrity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347349Panc-1005 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347365SDT Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347356HPAF-II 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347374qHTS for Hypoxia signaling pathway (HIF-1) antagonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347390Secretion counterscreen for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347379qHTS for Inflammasome Signaling Inhibitors: IL-1-beta AlphaLISA screen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347391qHTS for activators of Nrf2/ARE signaling pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347345OV-KATE Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347394Vero-766 cells viability qHTS against the NCATS CANVASS Library: Counterscreen for Zika virus inhibition assay2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347366KB-3-1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347375qHTS for Hypoxia signaling pathway (HIF-1) agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347367qHTS for ATAD5 Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347378qHTS for H2AX Agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347389qHTS assay for small molecule disruptors of mitochondrial membrane potential screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347353A2780 Cisplatin Sensitive Ovarian Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347377DH5-alpha competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347364KB-8-5-11 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347361HEK293 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347362Diaphorse counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347357HEK293 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347400Viability qHTS for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347371J3T Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347346HPAF-II Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347359HEK293 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,972)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902855 (57.42)18.7374
1990's1258 (25.30)18.2507
2000's587 (11.81)29.6817
2010's243 (4.89)24.3611
2020's29 (0.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.13 (24.57)
Research Supply Index8.54 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index66.93 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.08%)5.53%
Reviews90 (1.77%)6.00%
Case Studies4 (0.08%)4.05%
Observational0 (0.00%)0.25%
Other4,990 (98.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]